Greatmark Investment Partners Inc. increased its position in shares of Gilead Sciences Inc. (NASDAQ:GILD) by 7.5% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 36,550 shares of the biopharmaceutical company’s stock after buying an additional 2,565 shares during the period. Gilead Sciences comprises about 1.3% of Greatmark Investment Partners Inc.’s holdings, making the stock its 25th largest position. Greatmark Investment Partners Inc.’s holdings in Gilead Sciences were worth $2,892,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Van Hulzen Asset Management LLC raised its stake in Gilead Sciences by 9.1% in the second quarter. Van Hulzen Asset Management LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 100 shares during the period. Gemmer Asset Management LLC raised its stake in Gilead Sciences by 15.5% in the third quarter. Gemmer Asset Management LLC now owns 1,301 shares of the biopharmaceutical company’s stock valued at $103,000 after buying an additional 175 shares during the period. Joel Isaacson & Co. LLC raised its stake in Gilead Sciences by 20.8% in the second quarter. Joel Isaacson & Co. LLC now owns 1,310 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 226 shares during the period. Roble Belko & Company Inc raised its stake in Gilead Sciences by 340.5% in the second quarter. Roble Belko & Company Inc now owns 1,339 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 1,035 shares during the period. Finally, Pinkerton Retirement Specialists LLC raised its stake in Gilead Sciences by 9,305.9% in the second quarter. Pinkerton Retirement Specialists LLC now owns 1,599 shares of the biopharmaceutical company’s stock valued at $133,000 after buying an additional 1,582 shares during the period. Hedge funds and other institutional investors own 73.59% of the company’s stock.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Gilead Sciences Inc. (NASDAQ:GILD) traded up 0.44% during trading on Tuesday, hitting $74.87. 7,160,652 shares of the company were exchanged. The stock has a market capitalization of $98.64 billion, a PE ratio of 6.92 and a beta of 1.25. The firm’s 50 day moving average price is $74.54 and its 200-day moving average price is $80.07. Gilead Sciences Inc. has a 1-year low of $71.39 and a 1-year high of $107.38.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, November 1st. The biopharmaceutical company reported $2.75 EPS for the quarter, missing the Zacks’ consensus estimate of $2.87 by $0.12. The firm earned $7.40 billion during the quarter, compared to the consensus estimate of $7.47 billion. Gilead Sciences had a return on equity of 100.57% and a net margin of 47.74%. The business’s revenue for the quarter was down 9.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.22 earnings per share. Equities analysts predict that Gilead Sciences Inc. will post $11.47 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 29th. Shareholders of record on Thursday, December 15th will be issued a $0.47 dividend. The ex-dividend date of this dividend is Tuesday, December 13th. This represents a $1.88 dividend on an annualized basis and a yield of 2.51%. Gilead Sciences’s dividend payout ratio is presently 17.44%.

ILLEGAL ACTIVITY WARNING: “Gilead Sciences Inc. (GILD) Shares Bought by Greatmark Investment Partners Inc.” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another domain, it was illegally copied and republished in violation of US and international trademark & copyright law. The legal version of this report can be read at https://www.thecerbatgem.com/2016/11/29/gilead-sciences-inc-gild-shares-bought-by-greatmark-investment-partners-inc.html.

A number of analysts recently weighed in on the stock. Credit Suisse Group AG decreased their target price on shares of Gilead Sciences from $115.00 to $95.00 and set an “outperform” rating on the stock in a report on Wednesday, September 14th. Jefferies Group reaffirmed a “hold” rating on shares of Gilead Sciences in a report on Thursday, August 25th. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $108.00 target price on shares of Gilead Sciences in a report on Wednesday, August 31st. RBC Capital Markets decreased their target price on shares of Gilead Sciences from $95.00 to $90.00 and set an “outperform” rating on the stock in a report on Wednesday, November 2nd. Finally, Zacks Investment Research raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a report on Wednesday, September 14th. Ten equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and two have assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $97.90.

In other Gilead Sciences news, EVP Gregg H. Alton sold 5,000 shares of the business’s stock in a transaction dated Thursday, September 22nd. The shares were sold at an average price of $81.84, for a total value of $409,200.00. Following the completion of the transaction, the executive vice president now directly owns 132,964 shares in the company, valued at $10,881,773.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director John W. Madigan sold 105,000 shares of the company’s stock in a transaction dated Friday, November 18th. The shares were sold at an average price of $74.86, for a total transaction of $7,860,300.00. Following the transaction, the director now owns 121,761 shares in the company, valued at approximately $9,115,028.46. The disclosure for this sale can be found here. 1.40% of the stock is currently owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

5 Day Chart for NASDAQ:GILD

Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.